Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization

to related objects

The blockade of PD‐1/PD‐L1, which serves to “release the brake” of tumor immunity, represents a promising approach for treating various malignancies. However, the systemic immune‐related side effects significantly undermine its therapeutic efficacy. To address this dilemma, a photoactivatable and biocompatible prodrug cBMS‐1 based on the concept of photopharmacology is reported. The prodrug exhibits negligible toxicity but exerts effective PD‐1/PD‐L1 axis inhibition upon light irradiation, holding promising potential to achieve local activation of immune responses in clinical settings.

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization ; day:16 ; month:05 ; year:2022 ; extent:8
Advanced nanoBiomed research ; (16.05.2022) (gesamt 8)

Creator: Liu, Yuwei
Long, Kaiqi
Kang, Weirong
Wang, Tianyi
Wang, Weiping

DOI: 10.1002/anbr.202200017

URN: urn:nbn:de:101:1-2022051615102120864876

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:28 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Liu, Yuwei
Long, Kaiqi
Kang, Weirong
Wang, Tianyi
Wang, Weiping

Other Objects (12)

Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization

Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

Hochschulschrift

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers

High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers

Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1

Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization

Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

Hochschulschrift

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers

High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers

Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1

Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization

Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

Hochschulschrift

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers

High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers

Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1

Enhancing cancer care with improved checkpoint inhibitors : a focus on PD-1/PD-L1

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.